Canadian Rx-to-OTC Approval Process Could Be Smoother, GSK Exec Says
This article was originally published in The Tan Sheet
Executive Summary
Canada's Rx-to-OTC switch process should be streamlined and made more industry-friendly, according to GlaxoSmithKline regulatory executive Jennifer Denomme
You may also be interested in...
Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts
The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.
Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts
The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.
Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts
The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.